Amicus Therapeutics Announces First Quarter 2008 Financi... (of leasehold improvements ...)

Amicus Therapeutics Announces First Quarter 2008 Financial Results

Date:5/13/2008

of leasehold

improvements - - 1,030

Depreciation and amortization 297 321 3,115

In-process research and

development - - 418

Total operating expenses 10,232 12,448 144,638

Loss from operations (10,232) (9,288) (139,694)

Other income (expenses):

Interest income 693 1,702 9,643

Interest expense (92) (70) (1,500)

Change in fair value of

warrant liability (64) - (454)

Other expense - - (1,180)

Loss before tax benefit (9,695) (7,656) (133,185)

(Provision for)/benefit

from income taxes - (75) 620

Net loss (9,695) (7,731) (132,565)

Deemed dividend - - (19,424)

Preferred stock accretion (41) - (802)

Net loss attributable to

common stockholders $(9,736) $ (7,731) $(152,791)

Net loss attributable to

common stockholders per

common share - basic and

diluted $ (10.21) $(0.34)

Weighted-average common

shares outstanding -

basic and diluted 953,959 22,412,689

See accompanying notes to consolidated financial statements

Table 2

Amicus Therapeutics, Inc.

Reconciliation of GAAP to non-GAAP Measures for the Statement of Operations Information for Three Months Ended March 31, 2008

(Unaudited)

(In thousands, except share and per share amounts) <
'/>"/>

Post Your Comments:

Amicus Therapeutics Announces First Quarter 2008 Financi...(of leasehold improvements ...)